NOVEMBER 6, 2025
Filling a major public health need, studies continue to point to ibogaine as a viable treatment option for patients with opioid use disorder (OUD), according to a new systematic review and meta-analysis.
OUD remains a challenge to treat, as no FDA-approved medications with near-universal efficacy have been developed. While ibogaine has been used as an active in drug-assisted treatment for OUD with positive results, current evidence on the drug’s efficacy remains inconclusive.
In the
Filling a major public health need, studies continue to point to ibogaine as a viable treatment option for patients with opioid use disorder (OUD), according to a new systematic review and meta-analysis.
OUD remains a challenge to treat, as no FDA-approved medications with near-universal efficacy have been developed. While ibogaine has been used as an active in drug-assisted treatment for OUD with positive results, current evidence on the drug’s efficacy remains inconclusive.
In the study, the investigators performed an updated systematic review and single-arm meta-analysis of ibogaine-assisted therapy in patients undergoing treatment for OUD. The team searched several databases for studies with ibogaine as a main agent in drug-assisted OUD treatment and focused on several outcomes of interest, including reduction of withdrawal symptoms, decreased substance use, improvement of social functioning, and improvement of psychological symptoms.
Overall, they identified four observational studies of 120 patients who were predominantly male, white, and had a mean age of 33.52 years with an average of 4.26 previous treatment attempts.
The researchers used the Subjective Opiate Withdrawal Scale and the Addiction Severity Index to assess the studies.
The results show after evaluating withdrawal symptoms, there was a reported overall decrease of 12.62 (95% CI, 4.75%-20.48%; P=0.003; I²=83.05%). The investigators also observed significant positive changes in the social functioning and mental health over one year of patients.
The authors noted the high heterogeneity of the study could be explained by the relatively small sample size and absence of control groups.
“Our meta-analysis suggests that ibogaine demonstrates promising potential for the treatment of opioid use disorder, showing beneficial effects on opioid withdrawal symptoms, psychiatric outcomes, and social reintegration of affected individuals,” the authors wrote. “However, given the risk of bias inherent to the observational methodologies of the studies included in this meta-analysis, it is essential that randomized clinical trials be conducted to establish the efficacy and safety of ibogaine in this context.”
—Kenny Walter
